Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.此處係揭露針對抗原PDGFR-α之致標性結合劑以及此類劑之用途。更特定地,本發明係關於針對抗原PDGFR-α之完全人類單株抗體以及此類抗體之用途。本發明之觀點亦關於表現此類抗體之融合瘤及其它細胞株。該所述之致標性結合劑及抗體係可使用於診斷及治療和PDGFR-α之活性及/或過度表現相關聯之疾病。